Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake

总统癌症顾问委员会和疾病控制中心呼吁在 促进接种人乳头瘤病毒疫苗，包括为青春期男孩接种疫苗，因为 这种新疫苗的接种率仍然低得令人担忧。目前，只有不到15%的青春期男孩有 接种了HPV疫苗；因此，该人群中的大多数人仍有患口咽、肛门和阴茎的风险。 癌症。许多父母仍然不相信HPV疫苗的安全性和有效性，因此有效和 需要方便快捷的信息，以改善对这种疫苗的决策。青春期男孩的父母也 对接种HPV疫苗的担忧与对青春期女孩的不同，创造了对独特健康的需求 促进男孩接种疫苗的沟通干预措施。干预措施还需要解决 少数族裔人口和英语不是第一语言的人口面临的独特挑战。一本小说 将制作数字干预并评估其改善HPV疫苗结果的能力。 具体地说，将创建一个移动响应Web应用程序(“移动Web应用程序”)，其运行方式类似于 移动应用程序，但可在各种计算平台上运行，从个人台式机和笔记本电脑到 最新的智能手机和平板电脑。移动网络应用程序的内容将面向父母和青少年 居住在新墨西哥州的11-13岁男孩，是占多数的少数民族人口，占很大比例 西班牙裔、白人和美洲土著人。具体目标是：1)认真系统地开发一种 适用于智能手机、平板电脑和个人电脑的移动网络应用程序(BoyVac) 创新扩散原则，以提供有关采用HPV疫苗的有针对性的信息 青春期男性及其父母，特别是少数族裔青少年和父母；2)执行 BoyVac移动网络应用干预对HPV疫苗影响的全面严谨测试 通过随机疗效试验(BoyVac诉日常护理和习惯护理)的收养结果；以及3)检查 组件内移动网络应用程序使用与疫苗结果之间的剂量-反应关系 分析。采用整群随机前测-后测对照设计，共招募1800对 来自30个儿科诊所的父母和青春期男孩(每个诊所60名父母和男孩) 展望新墨西哥，新墨西哥大学健康科学中心的最佳实践项目 儿科。父母将接受基线调查，3个月的跟踪调查，9个月的跟踪调查 而男童接受HPV疫苗接种的记录将于9：00从诊所的医疗记录中获得- 一个月的随访。分析将检验这样的假设：1)干预组中有更多11-13岁的男孩 (BoyVac移动网页应用程序)将采用HPV疫苗的男孩在平时和常规护理中进行比较 小组和2)HPV疫苗的采用将通过以下理论媒介的改进进行中介 家长在干预组与平时照顾组和常规照顾组进行比较。

The President's Cancer Advisory Board and the Centers for Disease Control have called for renewed efforts in promoting vaccination for Human Papillomavirus (HPV), including vaccination for adolescent boys, because the uptake of this new vaccine remains alarmingly low. Currently, less than 15% of adolescent boys have received the HPV vaccine; thus, most of this population remains at risk for oropharyngeal, anal, and penile cancers. Many parents remain unconvinced of the safety and effectiveness of HPV vaccines, so effective and accessible messaging to improve decision-making on this vaccine is needed. Parents of adolescent boys also have different concerns about HPV vaccination than for adolescent girls, creating a need for unique health communication interventions to promote vaccine uptake among boys. Interventions also need to address the unique challenges of minority populations and populations for whom English is not the first language. A novel digital intervention will be produced and evaluated for its ability to improve HPV vaccine outcomes. Specifically, a mobile responsive web application (“mobile web app”) will be created that performs similar to a mobile app but runs on a variety of computing platforms from personal desktop and laptop computers to the latest smart phones and tablet computers. Mobile web app content will be targeted to parents and adolescent boys aged 11-13 years living in New Mexico, a majority-minority population with large proportions of Hispanics, Whites, and Native Americans. The specific aims are to: 1) carefully and systematically develop a mobile web app (BoyVac) for smart phones, tablet computers, and personal computers that will utilize Diffusion of Innovations principles to provide targeted information concerning HPV vaccine adoption to adolescent males and their parents, particularly minority adolescents and parents; 2) implement a comprehensive and rigorous test of the impact of the BoyVac mobile web app intervention on HPV vaccine adoption outcomes via a randomized efficacy trial (BoyVac v. usual and customary care); and 3) examine the dose-response relationships between mobile web app usage and vaccine outcomes within a components analysis. A group-randomized pretest-posttest controlled design will be implemented, recruiting 1800 pairs of parents and adolescent boys from 30 pediatric clinics (n=60 parents and boys per clinic) affiliated with the Envision New Mexico, a best practices program at the University of New Mexico Health Sciences Center's Department of Pediatrics. Parents will be surveyed at baseline, a 3-month follow-up, and a 9-month follow-up and records HPV vaccination adoption for the boys will be obtained from the clinics' medical records at the 9- month follow-up. Analyses will test the hypotheses that 1) more 11-13 year old boys in the intervention group (BoyVac mobile web app) will adopt the HPV vaccine than boys in the usual and customary care comparison group and 2) adoption of HPV vaccine will be mediated by improvements in theoretical mediators among parents in the intervention compared to the usual and customary care comparison group.